Windtree Therapeutics, Inc. Working Capital

Working Capital of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2020 was $21.4 Million (a 91.81% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -294.32%
  • Annual Working Capital for 2019 was $16 Million (a 219.6% increase from previous year)
  • Annual Working Capital for 2018 was $5.02 Million (a -152.71% decrease from previous year)
  • Annual Working Capital for 2017 was $-9.52 Million (a 53.67% increase from previous year)
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Windtree Therapeutics, Inc.

Most recent Working Capitalof WINT including historical data for past 10 years.

Interactive Chart of Working Capital of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $21.4 $11.16
2019 $16.04 $-11.02 $-5.65 $-0.89 $16.04
2018 $5.02 $-17.07 $-14.15 $-13.75 $5.02
2017 $-9.52 $-26.39 $-21.44 $-15.33 $-9.52
2016 $-6.2 $-0.44 $6.89 $16.69 $-6.2
2015 $29.73 $38.94 $16.89 $26.9 $29.73
2014 $37.73 $46.3 $55.62 $65.68 $37.73
2013 $75.38 $10.4 $21.56 $13.98 $75.38
2012 $16.11 $21.49 $33.94 $40.6 $16.11
2011 $-0.52 $2.68 $6.77 $14.13 $-0.52
2010 $2.92 $6.69 $14.37 $8.75 $2.92

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.